Histamine H2-receptor antagonists |
| |
| Authors: | R Pounder |
| |
| Affiliation: | 1. School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, England, United Kingdom of Great Britain and Northern Ireland;2. School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, England, United Kingdom of Great Britain and Northern Ireland;1. Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China;2. Department of Radiology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China;3. Interventional Medicine Center, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China;4. Interventional Radiology Institute, Sun Yat-sen University, Zhuhai 519000, China;5. Department of Radiology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China |
| |
| Abstract: | The first histamine H2-receptor antagonists were developed in the early 1970s, and they have a dominant role in today's management of peptic ulceration. The original regimens using either cimetidine or ranitidine attempted to control acidity across the 24 hours, but more 'modern' regimens use a large single dose of the H2-blocker in the evening, which produces a pulse of decreased intragastric acidity during the night with a normal acidity in the daytime. High-dose regimens using a new generation of extremely potent histamine H2-receptor antagonists may improve ulcer healing rates at 4 weeks, and may be particularly useful for the management of either severe oesophagitis or intractable duodenal ulceration. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
